Modality
mRNA
MOA
KRASG12Ci
Target
TROP-2
Pathway
Incretin
FSGSDMDCRC
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
→ Dec 2031
Phase 2Current
NCT04103924
1,349 pts·FSGS
2021-01→2031-12·Not yet recruiting
1,349 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-085.7y awayPh2 Data· FSGS
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2031-12-08 · 5.7y away
FSGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04103924 | Phase 2 | FSGS | Not yet recr... | 1349 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |